09:13 AM EDT, 07/28/2025 (MT Newswires) -- Lenz Therapeutics ( LENZ ) said Monday it has filed a New Drug Application with China's National Medical Products Administration for its eye drop LNZ100 to treat presbyopia.

The filing is based on results of phase 3 data from a trial in China that showed LNZ100 met primary and secondary endpoints, including significant three-lines or greater improvement in near vision without losing one line or more in distance visual acuity.

The submission triggers the first milestone under the companies' licensing agreement with Corxel covering Greater China.

Shares of Lenz Therapeutics ( LENZ ) were 4.3% higher in recent Monday premarket activity.